SEC Form 4 · accession 0001493152-26-035950
Inhibitor Therapeutics, Inc. · INTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francis E Odonnell Jr.
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
May 4, 2026
Accepted (ET)
Aug 4, 2026 · 11:55 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001042418
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 4, 2026 | A | 50,000 | $0.00 | A | 150,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.